Sugi Predict

Sugi Predict / Compounds / SCHEMBL31026257

SCHEMBL31026257

SCHEMBL31026257

Nc1ccc(C2(C(F)(F)F)CC2)cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS3 P29474 2/20 0.36
▸ NOS2 P35228 2/20 0.36
▸ PIK3CD O00329 2/20 0.35
▸ PIK3CA P42336 2/20 0.33
▸ MTOR P42345 2/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ GABRP O00591 2/20 0.32
▸ GABRD O14764 2/20 0.32
▸ GABRA1 P14867 2/20 0.32
▸ GABRB1 P18505 2/20 0.32
▸ GABRG2 P18507 2/20 0.32
▸ GABRB3 P28472 2/20 0.32
▸ GABRA5 P31644 2/20 0.32
▸ GABRA3 P34903 2/20 0.32
▸ GABRA2 P47869 2/20 0.32
▸ GABRB2 P47870 2/20 0.32
▸ GABRA4 P48169 2/20 0.32
▸ GABRE P78334 2/20 0.32
▸ GABRA6 Q16445 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25322547 0.78 TRPA1 (0.40) PIK3CDALOX5APSIGMAR1
SCHEMBL25358827 0.77 TRPA1 (0.35) SIGMAR1
SCHEMBL30531074 0.77 TRPA1 (0.35) SIGMAR1
SCHEMBL28053688 0.75 KMT2A (0.53) KDM4C
SCHEMBL24737534 0.75 NOS3 (0.40) NOS3NOS2PIK3CDPIK3CAMTOR
SCHEMBL16764551 0.74 ALDH1A1 (0.45) KDM4ESMN1; SMN2SIGMAR1
SCHEMBL25358564 0.74 CACNA1H (0.35) ALOX5APKDM4C
SCHEMBL30531070 0.74 CACNA1H (0.35) ALOX5APKDM4C
SCHEMBL27463527 0.73 NOS3 (0.52) NOS3NOS2KDM4EGABRPGABRD
Hydrochloric Acid SCHEMBL32670447 0.72 ALDH1A1 (0.43) KDM4ESMN1; SMN2SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4635942-A1 QUINOLINE DERIVATIVE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF Jiangsu Carephar Pharmaceutical Co., Ltd (CN) 2025-10-22 — — EP disclosed
US-12384773-B2 Thiazole compounds and methods of use thereof ARCUS BIOSCIENCES, INC. (US) 2025-08-12 — — US disclosed
WO-2025096979-A1 THIAZOLE COMPOUNDS AS KIT INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2025-05-08 — — WO disclosed
WO-2024152743-A1 QUINOLINE DERIVATIVE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF 江苏柯菲平医药股份有限公司 2024-07-25 — — WO disclosed
CN-118373771-A Quinoline derivative compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof 江苏柯菲平医药股份有限公司 2024-07-23 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12384773-B2 Thiazole compounds and methods of use thereof TPMT, CYP11B2, ABAT NOS3 3227/4885NOS2 3015/4885PIK3CD 4399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.